How much did Thermo Fisher pay for the Solventum business?

Thermo Fisher paid approximately $4.0 billion in cash. Earlier in 2025 the parties agreed to remove the Drinking Water Filtration business and reduce closing consideration by $100 million, and Solventum may pay up to $75 million more later.

What will the acquired business contribute to revenue?

The business is expected to generate about $750 million of revenue for the full year 2025. Thermo Fisher expects mid- to high-single-digit organic growth after the deal closes.

Will the acquisition affect Thermo Fisher's earnings?

Yes, in the short term. The deal is expected to be dilutive to adjusted EPS by $0.06 in the first year because of one-time stand-up costs and financing costs. Thermo Fisher expects strong day-one cost savings and about $125 million of adjusted operating income from synergies by year five.

Where will the business sit within Thermo Fisher?

The business is now called the Filtration and Separation business and is part of the Life Sciences Solutions segment. It will serve bioprocessing filtration and membranes customers, plus healthcare and industrial filtration markets.

What returns does management expect from the deal?

Management says the deal's long-term growth, margin expansion, and synergy opportunities make the financial returns very compelling, with an anticipated double-digit internal rate of return. The release does not provide a specific valuation multiple or a GAAP earnings forecast.

TMO 8-K SEC Disclosure

01—Abstract

Summary

Summary of the 8-K filed September 2, 2025. Cited figures are marked; the original filing is the authoritative source.

On September 2, 2025, Thermo Fisher Scientific (NYSE: TMO) disclosed in an 8-K (Item 8.01, with the press release as Exhibit 99.1) that it completed its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion^a in cash.

The business is now called Thermo Fisher's Filtration and Separation business and sits within the Life Sciences Solutions segment. It serves bioprocessing filtration, healthcare and industrial filtration, and membranes markets, and is expected to generate roughly $750 million^b of revenue in 2025. Management expects mid- to high-single-digit organic growth for the business, with margin expansion driven by the PPI Business System and meaningful synergy realization.

The deal is expected to be dilutive to adjusted EPS by $0.06^c in the first year, reflecting one-time stand-up costs and financing costs that offset day-one cost savings. Thermo Fisher targets about $125 million of adjusted operating income from revenue and cost synergies by year five, and it cites an anticipated double-digit internal rate of return. The transaction was reduced in scope earlier in 2025: the Drinking Water Filtration business was removed, closing consideration was cut by $100 million, and Solventum may pay Thermo Fisher up to $75 million tied to a future sale of that business or after three years.

The filing itself is brief and mainly furnishes the press release; it contains no new financial statements. Investors will mainly watch integration execution, whether synergies and margin targets are met, and the effect of the purchase on near-term EPS.

02—Key points

Key Highlights

Thermo Fisher completed its acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion in cash.
The business is now the Filtration and Separation business within the Life Sciences Solutions segment.
Expected 2025 revenue of approximately $750 million, with mid- to high-single-digit organic growth targeted.
Expected first-year dilution to adjusted EPS of $0.06, driven by stand-up and financing costs partly offset by day-one cost synergies.
Targeted approximately $125 million of adjusted operating income from synergies by year five, with an anticipated double-digit IRR.
Deal scope was reduced earlier in 2025: Drinking Water Filtration was removed, closing consideration cut by $100 million, and up to $75 million may be paid to Thermo Fisher later.
Strategic rationale: strengthens bioproduction filtration offerings and expands into ultra-pure water markets such as battery, semiconductor, and medical device manufacturing.

03—Questions

Frequently Asked Questions

How much did Thermo Fisher pay for the Solventum business?
Thermo Fisher paid approximately $4.0 billion in cash. Earlier in 2025 the parties agreed to remove the Drinking Water Filtration business and reduce closing consideration by $100 million, and Solventum may pay up to $75 million more later.
What will the acquired business contribute to revenue?
The business is expected to generate about $750 million of revenue for the full year 2025. Thermo Fisher expects mid- to high-single-digit organic growth after the deal closes.
Will the acquisition affect Thermo Fisher's earnings?
Yes, in the short term. The deal is expected to be dilutive to adjusted EPS by $0.06 in the first year because of one-time stand-up costs and financing costs. Thermo Fisher expects strong day-one cost savings and about $125 million of adjusted operating income from synergies by year five.
Where will the business sit within Thermo Fisher?
The business is now called the Filtration and Separation business and is part of the Life Sciences Solutions segment. It will serve bioprocessing filtration and membranes customers, plus healthcare and industrial filtration markets.
What returns does management expect from the deal?
Management says the deal's long-term growth, margin expansion, and synergy opportunities make the financial returns very compelling, with an anticipated double-digit internal rate of return. The release does not provide a specific valuation multiple or a GAAP earnings forecast.

04—Continue

← View all 8-K filings